These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1427452)

  • 1. Pulmonary embolism and intravenous high-dose desferrioxamine.
    Cianciulli P
    Haematologica; 1992; 77(4):368-9. PubMed ID: 1427452
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
    Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
    Minerva Pediatr; 2000 Apr; 52(4):235-41. PubMed ID: 11995208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 5. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P; Forte L; Sorrentino F; Palombi M; Papa G; Marciani MG
    Bone Marrow Transplant; 1993; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
    Cianciulli P; Sorrentino F; Forte L; Palombi M; Papa G; Meloni C; Taccone Gallucci M; Casciani CU
    Haematologica; 1992; 77(6):514-5. PubMed ID: 1289188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatic abscess due to Yersinia in a child with thalassemia].
    Brunel F; François P; Durand C; Croize J; Jeannoel P
    Pediatrie; 1993; 48(2):159-62. PubMed ID: 8393182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.
    Rego EM; Neto EB; Simões BP; Zago MA
    Am J Hematol; 1998 Aug; 58(4):340-1. PubMed ID: 9692403
    [No Abstract]   [Full Text] [Related]  

  • 14. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desferrioxamine and urinary zinc excretion in beta-thalassemia major.
    Uysal Z; Akar N; Kemahli S; Dincer N; Arcasoy A
    Pediatr Hematol Oncol; 1993; 10(3):257-60. PubMed ID: 8217542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin.
    De Gobbi M; Pasquero P; Brunello F; Paccotti P; Mazza U; Camaschella C
    Haematologica; 2000 Aug; 85(8):865-7. PubMed ID: 10942934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful desensitization of a child with desferrioxamine hypersensitivity.
    Patriarca G; Schiavino D; Nucera E; Pellegrino S; Valle D; Della Corte AM; Pagliari G
    J Investig Allergol Clin Immunol; 1995; 5(5):294-5. PubMed ID: 8574439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 19. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia.
    Aessopos A; Kati M; Tsironi M; Polonifi E; Farmakis D
    Haematologica; 2006 May; 91(5 Suppl):ECR11. PubMed ID: 16709519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.